CORAL GABLES, Fla.--(BUSINESS WIRE)--AlphaNet, Inc., a not-for-profit organization founded to improve the health of individuals with Alpha-1 Antitrypsin Deficiency (Alpha-1), is proud to announce the launch of AlphaNet Canada in conjunction with the Prolastin Direct Canada Program, sponsored by Grifols Canada Ltd.
AlphaNet Canada is a Canadian corporation based in Etobicoke, Ontario, and is dedicated to improving the lives of individuals with Alpha-1 who live in Canada. Founded by Alphas to serve Alphas, AlphaNet Canada is committed to serving Alpha-1 patients in Canada through the implementation of comprehensive health management services. Integrated support services for Alpha-1 patients, participation in clinical trials involving Alpha-1 therapies, and a comprehensive disease management and prevention program are hallmarks of the AlphaNet program to improve the quality of life of those affected by Alpha-1 Antitrypsin Deficiency.
AlphaNet Canada is governed by a Board of Directors, a majority of whom are Alphas and Canadian citizens. A portion of excess revenues from AlphaNet Canada will go to Alpha-1 Antitrypsin Deficiency Canada Inc. (aka Alpha-1 Canada), a not-for-profit corporation, to fund Alpha-1 programs and support awareness and advocacy.
Two AlphaNet Canada Coordinators have been trained in the health management concepts that have proven successful for the nearly 4,000 AlphaNet subscribers in the United States. The Canadian Coordinators will provide services to different geographical areas of Canada. One will serve Alphas living in Western Canada, and the other, bilingual (English/French) Coordinator, will serve Alphas in Eastern and Central Canada.
AlphaNet’s Disease Management and Prevention program will serve as the underpinning of the effort to improve the quality of lives of Canadian Alphas. This program has resulted in high augmentation therapy compliance with fewer exacerbations, unscheduled doctor visits and hospitalizations.
A secure technological infrastructure has been established to house the patient database in accordance with all applicable Canadian Federal privacy regulations including, The Privacy Act, the Personal Information Protection and Electronic Documents Act (PIPEDA), and other Provincial and Territorial Laws. AlphaNet Canada looks forward to working with Alpha-1 Canada, Grifols Canada and specialty pharmacy, Innomar Strategies to provide comprehensive health management services to Alphas in Canada.
Alpha-1 Antitrypsin Deficiency is one of North America’s most prevalent, potentially lethal hereditary disorders. Discovered in 1963, Alpha-1 can cause life-threatening lung and/or liver disease. It is a leading genetic killer of adults in North America and a leading cause of liver transplants in children. It is estimated that between 10,000 and 15,000 individuals in Canada are actively lung or liver affected and less than five percent of that population has been accurately diagnosed. Those with the disorder are known as Alphas.